Furthermore, high expression of TMEM52B in lung, breast, ovarian, liver, rectal, and thyroid cancer patients was significantly correlated with increased survival when only patients with tumors that expressed E-cadherin, at relatively low levels (below the median), were included in the KM-plotter analysis (Fig. 8c), suggesting that TMEM52B expression may compensate for relatively low levels of E-cadherin to suppress tumor progression, resulting in better survival. This evidence concerns the gene TMEM52B and thyroid gland carcinoma.